Granite Point Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Granite Point Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-20,000	Closed	-$954K	–	94
2019 Q1	$954K	Buy	+20,000	New	+$996K	0.09%	66
2018 Q2	–	Sell	-20,800	Closed	-$1.32M	–	122
2018 Q1	$1.32M	Sell	20,800 -9,200	-31%	-$592K	0.13%	51
2017 Q4	$1.84M	Hold	30,000	–	–	0.18%	34
2017 Q3	$1.91M	Buy	+30,000	New	+$1.75M	0.4%	31

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Granite Point Capital Management's BMY Position: Q2 2019 in Review

Granite Point Capital Management sold out of Bristol-Myers Squibb (BMY) in Q2 2019, closing a stake of 20,000 shares — an estimated $954K sold.

Granite Point Capital Management first reported a position in BMY in Q3 2017 and held it in 4 quarters. The position peaked at $1.91M in Q3 2017. 1,777 funds tracked by Wall St. Rank hold BMY as of Q2 2019.

Granite Point Capital Management reported no remaining Bristol-Myers Squibb position as of Q2 2019 after selling out during the quarter.
Granite Point Capital Management sold 20,000 Bristol-Myers Squibb shares in Q2 2019, an estimated $954K.
Granite Point Capital Management first reported a position in Bristol-Myers Squibb in Q3 2017 and held it in 4 quarters.
Granite Point Capital Management's Bristol-Myers Squibb position peaked at $1.91M in Q3 2017.
1,777 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2019.

Based on Granite Point Capital Management's 13F filing for Q2 2019, filed 29 Jul 2019.